• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

(11)C-左乙拉西坦的放射性合成:一种用于SV2A表达PET成像的潜在标志物。

Radiosynthesis of (11)C-Levetiracetam: A Potential Marker for PET Imaging of SV2A Expression.

作者信息

Cai Hancheng, Mangner Thomas J, Muzik Otto, Wang Ming-Wei, Chugani Diane C, Chugani Harry T

机构信息

PET Center, Children's Hospital of Michigan, Detroit Medical Center , Detroit, Michigan 48201, United States ; Departments of Pediatrics, Radiology, and Neurology, Wayne State University School of Medicine , Detroit, Michigan 48201, United States ; Department of Radiology and Advanced Imaging Research Center, University of Texas Southwestern Medical Center , Dallas, Texas 75390, United States ; Department of Radiology and Advanced Imaging Research Center, University of Texas Southwestern Medical Center , Dallas, Texas 75390, United States.

PET Center, Children's Hospital of Michigan, Detroit Medical Center , Detroit, Michigan 48201, United States ; Departments of Pediatrics, Radiology, and Neurology, Wayne State University School of Medicine , Detroit, Michigan 48201, United States ; Departments of Pediatrics, Radiology, and Neurology, Wayne State University School of Medicine , Detroit, Michigan 48201, United States.

出版信息

ACS Med Chem Lett. 2014 Aug 19;5(10):1152-5. doi: 10.1021/ml500285t. eCollection 2014 Oct 9.

DOI:10.1021/ml500285t
PMID:25313330
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4190623/
Abstract

The multistep preparation of (11)C-levetiracetam ((11)C-LEV) was carried out by a one-pot radiosynthesis with 8.3 ± 1.6% (n = 8) radiochemical yield in 50 ± 5.0 min. Briefly, the propionaldehyde was converted to propan-1-imine in situ as labeling precursor by incubation with ammonia. Without further separation, the imine was reacted with (11)C-HCN to form (11)C-aminonitrile. This crude was then reacted with 4-chlorobutyryl chloride and followed by hydrolysis to yield (11)C-LEV after purification by chiral high-performance liquid chromatography (HPLC). Both the radiochemical and enantiomeric purities of (11)C-LEV were >98%.

摘要

(11)C-左乙拉西坦((11)C-LEV)的多步制备通过一锅法放射性合成进行,在50±5.0分钟内放射化学产率为8.3±1.6%(n = 8)。简而言之,通过与氨孵育,将丙醛原位转化为丙-1-亚胺作为标记前体。无需进一步分离,亚胺与(11)C-HCN反应形成(11)C-氨基腈。然后将该粗品与4-氯丁酰氯反应,接着水解,通过手性高效液相色谱(HPLC)纯化后得到(11)C-LEV。(11)C-LEV的放射化学纯度和对映体纯度均>98%。

相似文献

1
Radiosynthesis of (11)C-Levetiracetam: A Potential Marker for PET Imaging of SV2A Expression.(11)C-左乙拉西坦的放射性合成:一种用于SV2A表达PET成像的潜在标志物。
ACS Med Chem Lett. 2014 Aug 19;5(10):1152-5. doi: 10.1021/ml500285t. eCollection 2014 Oct 9.
2
The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam.突触小泡蛋白SV2A是抗癫痫药物左乙拉西坦的结合位点。
Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9861-6. doi: 10.1073/pnas.0308208101. Epub 2004 Jun 21.
3
Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action.布立西坦,一种选择性高亲和力突触囊泡蛋白2A(SV2A)配体,具有脑通透性高和起效快的临床前证据。
Epilepsia. 2016 Feb;57(2):201-9. doi: 10.1111/epi.13267. Epub 2015 Dec 10.
4
Levetiracetam inhibits THP-1 monocyte chemotaxis and adhesion via the synaptic vesicle 2A.左乙拉西坦通过突触小泡2A抑制THP-1单核细胞趋化性和黏附。
Biochem Biophys Res Commun. 2020 Feb 15. doi: 10.1016/j.bbrc.2020.02.061.
5
Development and In Vivo Preclinical Imaging of Fluorine-18-Labeled Synaptic Vesicle Protein 2A (SV2A) PET Tracers.氟-18 标记突触小泡蛋白 2A(SV2A)正电子发射断层扫描(PET)示踪剂的研发及其在体内的临床前影像学研究。
Mol Imaging Biol. 2019 Jun;21(3):509-518. doi: 10.1007/s11307-018-1260-5.
6
Synaptic vesicle protein 2A tumoral expression predicts levetiracetam adverse events.突触囊泡蛋白 2A 的肿瘤表达可预测左乙拉西坦的不良反应事件。
J Neurol. 2019 Sep;266(9):2273-2276. doi: 10.1007/s00415-019-09410-0. Epub 2019 Jun 5.
7
Synaptic Vesicle Protein 2A Expression in Glutamatergic Terminals Is Associated with the Response to Levetiracetam Treatment.谷氨酸能终末中突触囊泡蛋白2A的表达与左乙拉西坦治疗反应相关。
Brain Sci. 2021 Apr 23;11(5):531. doi: 10.3390/brainsci11050531.
8
Facile and rapid one-step radiosynthesis of [(18)F]BAY94-9172 with a new precursor.[(18)F]BAY94-9172 的简便、快速一步法放射性合成及其新前体。
Nucl Med Biol. 2011 Jan;38(1):121-7. doi: 10.1016/j.nucmedbio.2010.06.009. Epub 2010 Aug 16.
9
Further evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein.进一步证明布瓦西坦和左乙拉西坦与突触囊泡 2A 蛋白的相互作用存在差异。
Epilepsia. 2018 Sep;59(9):e147-e151. doi: 10.1111/epi.14532. Epub 2018 Aug 24.
10
Evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein.布立西坦和左乙拉西坦与突触囊泡2A蛋白差异性相互作用的证据。
Epilepsia. 2017 Feb;58(2):255-262. doi: 10.1111/epi.13638. Epub 2016 Dec 24.

引用本文的文献

1
Carbon isotopic labelling of carboxylic acids enabled by organic photoredox-catalysed cyanation.有机光氧化还原催化氰化实现羧酸的碳同位素标记
Nat Synth. 2025 Jan;4(1):97-105. doi: 10.1038/s44160-024-00656-9. Epub 2024 Sep 27.
2
Network-based Molecular Constraints on Synaptic Density Alterations in Schizophrenia.基于网络的精神分裂症突触密度改变的分子制约因素
medRxiv. 2025 Mar 23:2025.03.22.25324465. doi: 10.1101/2025.03.22.25324465.
3
Advances in synaptic PET imaging and intervention with synapse-targeted small-molecular drugs for dementia diagnosis and therapy.用于痴呆症诊断和治疗的突触PET成像及突触靶向小分子药物干预的进展。
Fundam Res. 2024 Apr 21;5(1):63-71. doi: 10.1016/j.fmre.2024.04.013. eCollection 2025 Jan.
4
Synaptic changes in psychiatric and neurological disorders: state-of-the art of in vivo imaging.精神神经疾病的突触变化:活体成像的最新技术。
Neuropsychopharmacology. 2024 Nov;50(1):164-183. doi: 10.1038/s41386-024-01943-x. Epub 2024 Aug 12.
5
Challenges and rewards of in vivo synaptic density imaging, and its application to the study of depression.体内突触密度成像的挑战与回报,及其在抑郁症研究中的应用。
Neuropsychopharmacology. 2024 Nov;50(1):153-163. doi: 10.1038/s41386-024-01913-3. Epub 2024 Jul 22.
6
Exploring the Interactions between two Ligands, UCB-J and UCB-F, and Synaptic Vesicle Glycoprotein 2 Isoforms.探究 UCB-J 和 UCB-F 两种配体与突触小泡糖蛋白 2 异构体之间的相互作用。
ACS Chem Neurosci. 2024 May 15;15(10):2018-2027. doi: 10.1021/acschemneuro.4c00029. Epub 2024 May 3.
7
SV2A PET imaging in human neurodegenerative diseases.人类神经退行性疾病中的突触囊泡蛋白2A正电子发射断层显像
Front Aging Neurosci. 2024 Apr 18;16:1380561. doi: 10.3389/fnagi.2024.1380561. eCollection 2024.
8
Organocatalytic Asymmetric Synthesis of SynVesT-1, a Synaptic Density Positron Emission Tomography Imaging Agent.手性有机催化合成 SynVesT-1,一种突触密度正电子发射断层成像剂。
J Org Chem. 2022 Nov 4;87(21):14443-14451. doi: 10.1021/acs.joc.2c01895. Epub 2022 Oct 12.
9
PET Imaging in Animal Models of Alzheimer's Disease.阿尔茨海默病动物模型中的正电子发射断层扫描(PET)成像
Front Neurosci. 2022 May 24;16:872509. doi: 10.3389/fnins.2022.872509. eCollection 2022.
10
Synaptic Vesicle Glycoprotein 2A: Features and Functions.突触囊泡糖蛋白2A:特征与功能
Front Neurosci. 2022 Apr 28;16:864514. doi: 10.3389/fnins.2022.864514. eCollection 2022.

本文引用的文献

1
Evaluation of 18F-UCB-H as a novel PET tracer for synaptic vesicle protein 2A in the brain.评估 18F-UCB-H 作为一种新型的用于脑内突触小泡蛋白 2A 的 PET 示踪剂。
J Nucl Med. 2014 Aug;55(8):1336-41. doi: 10.2967/jnumed.113.136143. Epub 2014 Jun 16.
2
Discovery of heterocyclic nonacetamide synaptic vesicle protein 2A (SV2A) ligands with single-digit nanomolar potency: opening avenues towards the first SV2A positron emission tomography (PET) ligands.发现具有个位数纳摩尔效力的杂环非乙酰氨突触小体蛋白 2A(SV2A)配体:为开发首个 SV2A 正电子发射断层扫描(PET)配体开辟了道路。
ChemMedChem. 2014 Apr;9(4):693-8. doi: 10.1002/cmdc.201300482. Epub 2014 Jan 20.
3
Synaptic vesicle protein 2A: basic facts and role in synaptic function.突触小泡蛋白 2A:基本事实及其在突触功能中的作用。
Eur J Neurosci. 2013 Dec;38(11):3529-39. doi: 10.1111/ejn.12360. Epub 2013 Sep 16.
4
11CO2 fixation: a renaissance in PET radiochemistry.11CO2 固定:正电子发射断层扫描放射化学的复兴。
Chem Commun (Camb). 2013 Jun 25;49(50):5621-9. doi: 10.1039/c3cc42236d. Epub 2013 May 14.
5
Preclinical radiation dosimetry for the novel SV2A radiotracer [18F]UCB-H.新型 SV2A 放射性示踪剂 [18F]UCB-H 的临床前放射剂量学研究。
EJNMMI Res. 2013 May 7;3(1):35. doi: 10.1186/2191-219X-3-35.
6
Barriers to clinical translation with diagnostic drugs.诊断药物临床转化的障碍。
J Nucl Med. 2013 Mar;54(3):329-32. doi: 10.2967/jnumed.112.107615. Epub 2013 Jan 28.
7
Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model.左乙拉西坦抑制阿尔茨海默病模型中的神经元网络功能障碍,并逆转突触和认知缺陷。
Proc Natl Acad Sci U S A. 2012 Oct 16;109(42):E2895-903. doi: 10.1073/pnas.1121081109. Epub 2012 Aug 6.
8
Levetiracetam: a review of its use in epilepsy.左乙拉西坦:在癫痫中的应用评价。
Drugs. 2011 Mar 5;71(4):489-514. doi: 10.2165/11204490-000000000-00000.
9
Pharmacotherapeutics of Tourette syndrome and stereotypies in autism.自闭症抽动秽语综合征和刻板行为的药物治疗。
Semin Pediatr Neurol. 2010 Dec;17(4):254-60. doi: 10.1016/j.spen.2010.10.008.
10
Is levetiracetam different from other antiepileptic drugs? Levetiracetam and its cellular mechanism of action in epilepsy revisited.左乙拉西坦与其他抗癫痫药物有何不同?重新审视左乙拉西坦及其在癫痫中的细胞作用机制。
Ther Adv Neurol Disord. 2008 Jul;1(1):13-24. doi: 10.1177/1756285608094212.